- Home
- SPOK vs ATYR Comparison
SPOK vs ATYR Comparison
Compare SPOK & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPOK
- ATYR
- Stock Information
- Founded
- SPOK 2004
- ATYR 2005
- Country
- SPOK United States
- ATYR United States
- Employees
- SPOK N/A
- ATYR N/A
- Industry
- SPOK Telecommunications Equipment
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPOK Telecommunications
- ATYR Health Care
- Exchange
- SPOK Nasdaq
- ATYR Nasdaq
- Market Cap
- SPOK 329.2M
- ATYR 330.7M
- IPO Year
- SPOK 1992
- ATYR 2015
- Fundamental
- Price
- SPOK $15.98
- ATYR $3.84
- Analyst Decision
- SPOK Hold
- ATYR Strong Buy
- Analyst Count
- SPOK 1
- ATYR 6
- Target Price
- SPOK $15.00
- ATYR $18.60
- AVG Volume (30 Days)
- SPOK 155.3K
- ATYR 1.9M
- Earning Date
- SPOK 04-30-2025
- ATYR 03-13-2025
- Dividend Yield
- SPOK 7.85%
- ATYR N/A
- EPS Growth
- SPOK N/A
- ATYR N/A
- EPS
- SPOK 0.73
- ATYR N/A
- Revenue
- SPOK $137,653,000.00
- ATYR $235,000.00
- Revenue This Year
- SPOK $3.51
- ATYR $1,387.23
- Revenue Next Year
- SPOK N/A
- ATYR $873.22
- P/E Ratio
- SPOK $21.82
- ATYR N/A
- Revenue Growth
- SPOK N/A
- ATYR N/A
- 52 Week Low
- SPOK $13.24
- ATYR $1.42
- 52 Week High
- SPOK $17.96
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- SPOK 42.34
- ATYR 53.78
- Support Level
- SPOK $15.52
- ATYR $2.98
- Resistance Level
- SPOK $16.86
- ATYR $4.32
- Average True Range (ATR)
- SPOK 0.42
- ATYR 0.40
- MACD
- SPOK -0.09
- ATYR 0.06
- Stochastic Oscillator
- SPOK 31.08
- ATYR 70.28
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. It reports three market segments namely Healthcare, Government, and Large enterprise. The company provides paging services and software solutions in the United States and abroad. It provides services such as Value-Added Services, Advisory Services, Assessment Services and Adoption Services.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.